||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Sphere Medical Share Discussion Threads
Showing 1176 to 1198 of 1200 messages
|This is how I see things. Figures for average income per hospital taken from sphere presentation last week (Also available on Sphere website in December final results). Sales volumes also taken from Sphere presentation for 2017. No figures available for 2018 so I have assumed double the takeup of year 1 which seems reasonable once the snowball starts rolling.
I have assumed most sales are to large teaching hospitals to start with and up until July there are no additional production costs as the facilities are already there and under-utilized. From October cost of sales is 35% of income as TD brokers note.
On top of all that I've assumed a £2m risk headroom which would give a cash requirement of £5m. Of course if the sales profile does turn out as modeled further loans would be easily attainable.
Since Woodford has already put in around £6m on his own, another £5m doesn't seem so much.|
|Me too CC
Unfortunately no one blows a whistle at the bottom, or rings a bell at the top (not that there ever was a "top" for Sphere) otherwise we would all be joining the idle rich!|
|Well someone believes. A nice 170k delayed buy and the bid moving up again today.
I hoping that's the bottom in now and this time the move up isn't based on short term speculators|
The shares are bit more perky today.
Director buying perhaps? That would be nice|
|Yeah - I have lots more to say but a bit busy right now. This is all I have time for until lunch. I've posted this elsewhere earlier today.
"In short I am persuaded that P4/P4+ is a killer product that will sell worldwide. The presentation also went on to discuss how their patented technology will be leveraged outside of the ICU which would expand our market way beyond the current P4/P4+/P5 market. I think none of this value is really understood by the market or in the price.
It's all down to timing. It's a balance of sales curve vs cash burn vs perception of success. Clearly the market's perception of success has been very different to mine and the timing of my investment so far has been too early.
PI's aren't interested in this sort of stock. It's clear they don't understand it and are more excited by oil and mining.
I think it's a bargain. I tried to buy another 100k this morning but the MM's wouldn't give me any for less than 6.0. I've already got 450k which is plenty. 550k would have been nice but I'm not greedy. I'm feeling good. If the price goes up I'm happy, if the price pulls back I'm happy too. A good place to be.
I have the presentation in my inbox now:
"Proxima currently addresses only a part of the health
Patient monitoring also required in other parts of and
outside of the hospital
Sepsis, chronic diseases, wellbeing of elderly
Potential for broader applicability of Proxima sensor
Explore product variants for other parts of the healthcare
So, take the tech and the patents and transfer to new products for use inside and outside hospital inc. GP surgery and patients homes. Telehealth is one of the things the NHS talks about endlessly when it comes to cost savings|
|Did you make it last night?|
|Trending and scheduling now on the monitor.
|Link to annual report for year ending December 2016 (published today) is here:
No date given for the AGM which I would like to attend this year.
>>>>CC looks like I might not make it to the meeting on Thursday, if I don't make it, try to pin him down on director share purchases (where are they?)|
|Agreed Del - I'm more interested it the tone and body language.|
|Unless we get a sales update before then....I can only see it been more of the same...
But good luck to the both of you and have a good evening....|
|I'm going but will have to leave just after 9 to get the last train home as I'm not staying in London on Thursday night.
Looking forward to seeing you there Tim.
It looks like Valirx may have pulled out - it's not clear.|
|Short video from SPHR.....
|I will definitely go along on March 23rd, so hopefully I will see you there CC.|
|I am tempted to go. A Sphere/Valirix double bill would be an interesting follow up to their last double bill around September especially after George from Valirix "it bloody works"
I'm have to make a decision as I am currently planning to do something else.|
|Re:Sphere medical proxima 3 and now 4 blood analytic device:
Yes,this share/company could eventually make serious sales and then it would take off.
As others have stated,this is a well thought out,labour saving,time saving and error avoiding device.
There is nothing wrong with the product,quite the contrary.
The company just needs to relentlessly and skillfully find a way to sell the product in useful quantities.
What we seem to keep hearing here is that the lack of meaningful sales is entirely due to the red tape,apathy and bureaucracy in the hospital systems, that lack of meaningful sales is not Sphere Medical's fault in any way.
What we do not seem to be hearing is: how Sphere Medical is going to find a way around this .
New blood is needed to step over any obstacles and sell Proxima Four more agressively or more intelligently.
The sales team needs to pick up the pace.
I will hang onto my shares till the situation ends either way.
Time for my medication.
|ls:> Excellent summary - imo unless sales traction is swiftly established this could go the way of many "must have"!! small medical device companies - if I was not worried re either a placing or similar dilutive funding from which PI's are excluded I would start building a position - However not all chairmen are as supportive of PI's as DB of SCE.
This also applies to HAYT which is looking interesting but also needs a relativly large equity injection (imo) - Trust you are well -|
|I am so tempted to buy.Just looking at the strength of support given both by IIs and SVB make me feel there must be some value here.There largest competitor is market inertia and it is worth examining that.Whilst it is logical to expect medical practitioners to welcome a device that will improve both quality and efficiency of care, there is still a capital cost of implementation, an operating cost for consumables, a need to add a new consumable into the stocking and planning processes and a requirement to train staff. To my mind, inertia to such change is very difficult to challenge. In addition, there is so little competition in European health care that even public demand for a change to such technology will meet deaf ears.This product could well gain traction but I think we are two to three years from break-even.They do need to raise money in the near future; I don't think £7m is enough, I think they need nearer £12m.Given the current share price, a placing to finance commercialisation would be horribly dilutive. Hence the use of SVB whilst they "evaluate financing options".A likely scenario is that they have a capital profit-sharing deal with an outfit like Lanstead. In essence there is a placing, but instead of upfront cash, the company get a monthly payment linked to the current share price. If the share price rises, the payments go up pro-rata (and vice-versa of course).IMM did a similar deal last year and whilst many expected a "death spiral" in the share price, the opposite happened.In that regard, buying now may prove quite an astute move.Dilemmas, dilemmas.|
|I agree with you Tim...on both counts...Yes he does look similar to your chancellor.... but I too had expected an open offer (before the SVB loan announcement) at this year's results.....and had thought it factored in.
So what next. The CFO has said that they are very aware that the market will be watching for signs of some traction in sales...in the next few months.....
I think the SVB loan may be an indicator in advance.
But then....I am a very long term holder, so I would say that wouldn't I?
Accumulated a few more recently, on the back of no new issuing of equity!!!!!|
|On a slightly tangential topic: has anyone else noticed that Richard Wright bears more than a passing resemblance to our beloved Chancellor of the Exchequer: Philip Hammond|
Yes indeed, although had I assumed (incorrectly?) that those factors were already in the price prior to results.|
|timbo003: Worries about funding (imo) Risk of low ball placing or dilutive convertible loan.|
|I haven't seen either video yet Del and I probably won't do so until the weekend (the WiFi at this hotel sucks).
I'm surprised at the share price reaction to the results, the outlook now seems somewhat better than I was expecting.|